DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera.
Overview
abstract
DNMT3A mutations in patients with polycythemia vera were heterogeneous and not enriched in interferon alfa-treated patients. DNMT3A mutations had no detectable impact on the hematologic response, molecular response, or survival outcomes.
